AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for 5-hydroxytryptamine receptor 7

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P34969

UPID:

5HT7R_HUMAN

Alternative names:

5-HT-X; Serotonin receptor 7

Alternative UPACC:

P34969; B5BUP6; P78336; P78372; P78516; Q5VX01; Q5VX02; Q5VX03

Background:

The 5-hydroxytryptamine receptor 7, also known as 5-HT7 or Serotonin receptor 7, is a pivotal receptor for serotonin, a key neurotransmitter influencing mood, cognition, and perception. This receptor's activity is primarily mediated through G proteins that activate adenylate cyclase, playing a crucial role in transmitting serotonin signals.

Therapeutic significance:

Understanding the role of 5-hydroxytryptamine receptor 7 could open doors to potential therapeutic strategies. Its involvement in neurotransmission suggests its potential impact on mood disorders and cognitive functions, making it a target of interest in psychiatric and neurological research.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.